Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 2290-2292, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bassion, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bassion, S.
Related Collections
Right arrow Laboratory Management
(Clinical Chemistry. 2002;48:2290-2292.)
© 2002 American Association for Clinical Chemistry, Inc.

Letters

Toward a Laboratory Data Interchange Standard for Clinical Trials

Susan Bassion

Clinical Data Interchange, Standards Consortium, PO Box 162033, Austin, TX 78716-2033, Fax 512-301-5480

E-mail s.bassion@worldnet.att.net

The first 20% of the full text of this article appears below.


To the Editor:

In 2001, an estimated 2.3 million people in the United States participated in and completed a clinical trial: 750 000 in government-sponsored clinical trials, 850 000 in industry-sponsored Phase I to III clinical trials, and 700 000 in industry sponsored Phase IV clinical trials (1). Major medical center participation in the conduct of clinical trials grew strongly in 2001. More than 65% of academic health centers have established centralized clinical trial offices that encourage and support the involvement of their departments and staff in the conduct of clinical trials (1). Many of the laboratories in those institutions are asked to support investigator participation. Clinical chemistry testing is the mainstay of the drug-safety tests that underlie all clinical trials, and laboratory data derived from tests of both drug safety and efficacy have been estimated to be as much as 60–80% of the data generated during the conduct of clinical trials. Because of this, laboratories are extremely important players in the clinical trial process.

Much time and effort is involved in the transfer of clinical trial laboratory data among the parties involved: the reference, performing, or central laboratory; contract-research organization (CRO); pharmaceutical company; and pharmaceutical partners. Some central clinical . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.